180 related articles for article (PubMed ID: 14977581)
21. Nanoparticle transport across the blood brain barrier.
Grabrucker AM; Ruozi B; Belletti D; Pederzoli F; Forni F; Vandelli MA; Tosi G
Tissue Barriers; 2016; 4(1):e1153568. PubMed ID: 27141426
[TBL] [Abstract][Full Text] [Related]
22. CNS Delivery of Nucleic Acid Therapeutics: Beyond the Blood-Brain Barrier and Towards Specific Cellular Targeting.
D'Souza A; Nozohouri S; Bleier BS; Amiji MM
Pharm Res; 2023 Jan; 40(1):77-105. PubMed ID: 36380168
[TBL] [Abstract][Full Text] [Related]
23. Elucidation of gene function using C-5 propyne antisense oligonucleotides.
Flanagan WM; Su LL; Wagner RW
Nat Biotechnol; 1996 Sep; 14(9):1139-45. PubMed ID: 9631067
[TBL] [Abstract][Full Text] [Related]
24. Novel non-endocytic delivery of antisense oligonucleotides.
Dokka S; Rojanasakul Y
Adv Drug Deliv Rev; 2000 Oct; 44(1):35-49. PubMed ID: 11035196
[TBL] [Abstract][Full Text] [Related]
25. [Development of Noninvasive Drug Delivery Systems to the Brain for the Treatment of Brain/Central Nervous System Diseases].
Kanazawa T
Yakugaku Zasshi; 2018; 138(4):443-450. PubMed ID: 29607986
[TBL] [Abstract][Full Text] [Related]
26. Delivery of therapeutic agents to the central nervous system: the problems and the possibilities.
Begley DJ
Pharmacol Ther; 2004 Oct; 104(1):29-45. PubMed ID: 15500907
[TBL] [Abstract][Full Text] [Related]
27. Intrathecal Delivery of Antisense Oligonucleotides in the Rat Central Nervous System.
Chen Y; Mazur C; Luo Y; Sun L; Zhang M; McCampbell A; Tomassy GS
J Vis Exp; 2019 Oct; (152):. PubMed ID: 31736489
[TBL] [Abstract][Full Text] [Related]
28. Nanotechnological advances for the delivery of CNS therapeutics.
Wong HL; Wu XY; Bendayan R
Adv Drug Deliv Rev; 2012 May; 64(7):686-700. PubMed ID: 22100125
[TBL] [Abstract][Full Text] [Related]
29. Drug and gene targeting to the brain with molecular Trojan horses.
Pardridge WM
Nat Rev Drug Discov; 2002 Feb; 1(2):131-9. PubMed ID: 12120094
[TBL] [Abstract][Full Text] [Related]
30. Antisense oligonucleotides for target validation in the CNS.
Ho SP; Hartig PR
Curr Opin Mol Ther; 1999 Jun; 1(3):336-43. PubMed ID: 11713799
[TBL] [Abstract][Full Text] [Related]
31. Brain drug targeting and gene technologies.
Pardridge WM
Jpn J Pharmacol; 2001 Oct; 87(2):97-103. PubMed ID: 11700018
[TBL] [Abstract][Full Text] [Related]
32. Antisense oligonucleotides: the state of the art.
Aboul-Fadl T
Curr Med Chem; 2005; 12(19):2193-214. PubMed ID: 16178780
[TBL] [Abstract][Full Text] [Related]
33. Antisense oligonucleotides for haematological malignancies.
Cotter FE
Haematologica; 1999 Jun; 84 Suppl EHA-4():19-22. PubMed ID: 10907458
[No Abstract] [Full Text] [Related]
34. Antisense Oligonucleotide-Based Therapy for Neuromuscular Disease.
Sardone V; Zhou H; Muntoni F; Ferlini A; Falzarano MS
Molecules; 2017 Apr; 22(4):. PubMed ID: 28379182
[TBL] [Abstract][Full Text] [Related]
35. A hitchhiker's guide to antisense and nonantisense biochemical pathways.
Branch AD
Hepatology; 1996 Dec; 24(6):1517-29. PubMed ID: 8938189
[TBL] [Abstract][Full Text] [Related]
36. Distribution and Penetration of Intracerebroventricularly Administered 2'OMePS Oligonucleotide in the Mouse Brain.
Casaca-Carreira J; Temel Y; Larrakoetxea I; Jahanshahi A
Nucleic Acid Ther; 2017 Feb; 27(1):4-10. PubMed ID: 27753537
[TBL] [Abstract][Full Text] [Related]
37. Site and mechanism of antisense inhibition by C-5 propyne oligonucleotides.
Moulds C; Lewis JG; Froehler BC; Grant D; Huang T; Milligan JF; Matteucci MD; Wagner RW
Biochemistry; 1995 Apr; 34(15):5044-53. PubMed ID: 7536034
[TBL] [Abstract][Full Text] [Related]
38. Convection-enhanced delivery: from mechanisms to clinical drug delivery for diseases of the central nervous system.
Saito R; Tominaga T
Neurol Med Chir (Tokyo); 2012; 52(8):531-8. PubMed ID: 22976134
[TBL] [Abstract][Full Text] [Related]
39. Nanomedicines for the Treatment of CNS Diseases.
Reynolds JL; Mahato RI
J Neuroimmune Pharmacol; 2017 Mar; 12(1):1-5. PubMed ID: 28150132
[TBL] [Abstract][Full Text] [Related]
40. Cholesterol-functionalized DNA/RNA heteroduplexes cross the blood-brain barrier and knock down genes in the rodent CNS.
Nagata T; Dwyer CA; Yoshida-Tanaka K; Ihara K; Ohyagi M; Kaburagi H; Miyata H; Ebihara S; Yoshioka K; Ishii T; Miyata K; Miyata K; Powers B; Igari T; Yamamoto S; Arimura N; Hirabayashi H; Uchihara T; Hara RI; Wada T; Bennett CF; Seth PP; Rigo F; Yokota T
Nat Biotechnol; 2021 Dec; 39(12):1529-1536. PubMed ID: 34385691
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
